Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Average Rating of “Moderate Buy” by Analysts

Revance Therapeutics logo

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) have been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the stock, reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $39.00.

Several equities analysts recently issued reports on RVNC shares. Cowen raised their price target on Revance Therapeutics from $55.00 to $65.00 in a research report on Thursday, September 8th. Barclays raised their target price on shares of Revance Therapeutics from $22.00 to $35.00 and gave the stock an “overweight” rating in a report on Friday, September 9th. Guggenheim upped their price target on shares of Revance Therapeutics to $35.00 in a report on Monday, August 15th. Wells Fargo & Company raised their price target on shares of Revance Therapeutics from $17.00 to $24.00 and gave the stock an “equal weight” rating in a report on Thursday, August 25th. Finally, The Goldman Sachs Group assumed coverage on shares of Revance Therapeutics in a research note on Thursday, September 22nd. They set a “buy” rating and a $33.00 price objective for the company.

Insiders Place Their Bets

In other news, SVP Dwight Moxie sold 11,000 shares of Revance Therapeutics stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $27.07, for a total transaction of $297,770.00. Following the sale, the senior vice president now owns 31,694 shares of the company’s stock, valued at approximately $857,956.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Advisor Group Holdings Inc. grew its stake in Revance Therapeutics by 60.6% in the first quarter. Advisor Group Holdings Inc. now owns 2,838 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,071 shares during the period. Point72 Hong Kong Ltd bought a new position in shares of Revance Therapeutics in the 2nd quarter worth about $92,000. Prospera Financial Services Inc purchased a new position in Revance Therapeutics during the 1st quarter valued at about $122,000. Corton Capital Inc. bought a new stake in Revance Therapeutics during the second quarter worth about $162,000. Finally, Sciencast Management LP purchased a new stake in Revance Therapeutics in the second quarter worth about $165,000. Hedge funds and other institutional investors own 77.08% of the company’s stock.

Revance Therapeutics Price Performance

RVNC stock opened at $24.94 on Thursday. The firm has a market cap of $1.82 billion, a P/E ratio of -6.48 and a beta of 0.92. The firm’s fifty day moving average is $21.27 and its 200 day moving average is $17.72. Revance Therapeutics has a 52 week low of $11.27 and a 52 week high of $29.58. The company has a debt-to-equity ratio of 14.80, a quick ratio of 3.20 and a current ratio of 3.38.

Revance Therapeutics (NASDAQ:RVNC – Get Rating) last posted its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.03. The business had revenue of $28.37 million during the quarter, compared to analyst estimates of $27.64 million. Revance Therapeutics had a negative net margin of 265.04% and a negative return on equity of 497.77%. Research analysts predict that Revance Therapeutics will post -3.69 earnings per share for the current year.

Revance Therapeutics Company Profile

(Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Further Reading

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to

Before you consider Revance Therapeutics, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Revance Therapeutics wasn’t on the list.

While Revance Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source link